Further, siRNA-mediated knockdown of ATG4B and HER2 resulted in a decrease of breast cancer cell viability, and a combination of ATG4B knockdown with the HER2 inhibitor trastuzumab resulted in a strong reduction of cell viability in HER2-overexpressing cells [81]. This evidence concerns the gene ERBB2 and breast cancer.